Insmed Incorporated (NASDAQ:INSM) was the target of unusually large options trading on Monday. Investors bought 862 put options on the stock. This is an increase of 1,005% compared to the typical daily volume of 78 put options.
In other news, Director Donald J. Hayden, Jr. sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $32.50, for a total value of $487,500.00. Following the transaction, the director now directly owns 71,131 shares of the company’s stock, valued at approximately $2,311,757.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.10% of the stock is owned by insiders.
Hedge funds have recently bought and sold shares of the stock. SG Americas Securities LLC bought a new position in Insmed in the 2nd quarter worth approximately $129,000. BNP Paribas Arbitrage SA raised its position in Insmed by 666.7% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 7,498 shares of the biopharmaceutical company’s stock worth $129,000 after purchasing an additional 6,520 shares during the last quarter. UBS Asset Management Americas Inc. bought a new position in Insmed in the 2nd quarter worth approximately $187,000. Virtu KCG Holdings LLC bought a new position in Insmed in the 2nd quarter worth approximately $201,000. Finally, Redmile Group LLC bought a new position in Insmed in the 2nd quarter worth approximately $212,000. Hedge funds and other institutional investors own 95.28% of the company’s stock.
Insmed (INSM) opened at $29.21 on Thursday. The company has a quick ratio of 15.21, a current ratio of 15.21 and a debt-to-equity ratio of 0.13. Insmed has a 1 year low of $11.49 and a 1 year high of $32.94.
Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.